Metadata
- Name
- Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT03012321
- Description
- This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men
with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have
ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a
1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes including
FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2,
MSH6, BRIP1, or FAM175A defects will be assigned to Arm IV with single agent olaparib. - Data or Study Types
- clinical trial
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2017
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT03012321
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT03012321